262 related articles for article (PubMed ID: 28696366)
21. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
22. Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma.
Sa JK; Kim SH; Lee JK; Cho HJ; Shin YJ; Shin H; Koo H; Kim D; Lee M; Kang W; Hong SH; Kim JY; Park YW; Song SW; Lee SJ; Joo KM; Nam DH
Neuro Oncol; 2019 Feb; 21(2):222-233. PubMed ID: 29939324
[TBL] [Abstract][Full Text] [Related]
23. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases.
Xu Y; Wang K; Yu Q
Oncotarget; 2016 Oct; 7(43):70080-70091. PubMed ID: 27661120
[TBL] [Abstract][Full Text] [Related]
24. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.
Rothenberger NJ; Stabile LP
Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28441771
[TBL] [Abstract][Full Text] [Related]
25. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
26. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
27. Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.
Olmez I; Zhang Y; Manigat L; Benamar M; Brenneman B; Nakano I; Godlewski J; Bronisz A; Lee J; Abbas T; Abounader R; Purow B
Cancer Res; 2018 Aug; 78(15):4360-4369. PubMed ID: 29844123
[TBL] [Abstract][Full Text] [Related]
28. MET deregulation in breast cancer.
Minuti G; Landi L
Ann Transl Med; 2015 Aug; 3(13):181. PubMed ID: 26366398
[TBL] [Abstract][Full Text] [Related]
29. Verbascoside suppresses the migration and invasion of human glioblastoma cells via targeting c-Met-mediated epithelial-mesenchymal transition.
Hei B; Wang J; Wu G; Ouyang J; Liu RE
Biochem Biophys Res Commun; 2019 Jul; 514(4):1270-1277. PubMed ID: 31113618
[TBL] [Abstract][Full Text] [Related]
30. UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT.
Huang P; Guo Y; Zhao Z; Ning W; Wang H; Gu C; Zhang M; Qu Y; Zhang H; Song Y
Aging (Albany NY); 2020 Jun; 12(11):10275-10289. PubMed ID: 32491994
[TBL] [Abstract][Full Text] [Related]
31. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J
FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097
[TBL] [Abstract][Full Text] [Related]
32. Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.
Walsh AM; Kapoor GS; Buonato JM; Mathew LK; Bi Y; Davuluri RV; Martinez-Lage M; Simon MC; O'Rourke DM; Lazzara MJ
Mol Cancer Res; 2015 Aug; 13(8):1227-37. PubMed ID: 25934697
[TBL] [Abstract][Full Text] [Related]
33. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
[TBL] [Abstract][Full Text] [Related]
34. miRNA-124-3p/neuropilin-1(NRP-1) axis plays an important role in mediating glioblastoma growth and angiogenesis.
Zhang G; Chen L; Khan AA; Li B; Gu B; Lin F; Su X; Yan J
Int J Cancer; 2018 Aug; 143(3):635-644. PubMed ID: 29457830
[TBL] [Abstract][Full Text] [Related]
35. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
36. The role of HGF/c-MET signaling pathway in lymphoma.
Lam BQ; Dai L; Qin Z
J Hematol Oncol; 2016 Dec; 9(1):135. PubMed ID: 27923392
[TBL] [Abstract][Full Text] [Related]
37. Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.
Owusu BY; Galemmo R; Janetka J; Klampfer L
Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28420162
[TBL] [Abstract][Full Text] [Related]
38. Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility.
Li R; Knight JF; Park M; Pendergast AM
PLoS One; 2015; 10(5):e0124960. PubMed ID: 25946048
[TBL] [Abstract][Full Text] [Related]
39. Migration of mesenchymal stem cells towards glioblastoma cells depends on hepatocyte-growth factor and is enhanced by aminolaevulinic acid-mediated photodynamic treatment.
Vogel S; Peters C; Etminan N; Börger V; Schimanski A; Sabel MC; Sorg RV
Biochem Biophys Res Commun; 2013 Feb; 431(3):428-32. PubMed ID: 23333382
[TBL] [Abstract][Full Text] [Related]
40. Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Otani Y; Fujimura A; Fujii K; Tomita Y; Hattori Y; Uneda A; Tsuboi N; Kaneda K; Makino K; Date I
Acta Neuropathol Commun; 2020 Apr; 8(1):42. PubMed ID: 32248843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
